Literature DB >> 12021625

Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.

Birgitta Pettersson1, Sven Almer, Freidoun Albertioni, Stefan Söderhäll, Curt Peterson.   

Abstract

This study examined the role of thiopurine methyltransferase (TPMT) polymorphism in the metabolism and clinical effects of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease and childhood leukemia. The current hypothesis is that the cytotoxic effects of thiopurines are caused by the incorporation of thioguanine nucleotides into DNA. In this context, S-methylation catalyzed by TPMT can be regarded as a competing metabolic pathway. The authors assayed the TPMT activity in red blood cells from 122 patients treated with azathioprine or 6-mercaptopurine (83 adults with inflammatory bowel disease and 39 children with acute lymphoblastic leukemia) and in 290 untreated controls (219 adult blood donors and 71 children). The concentrations of thioguanine nucleotides and methylthioinosine monophosphate were also assayed in red blood cells from the patients. The TPMT activity and the concentrations of methylthioinosine monophosphate and thioguanine nucleotides were higher in children than in adults. All children but no adult patient received concomitant methotrexate. Interaction between methotrexate and 6-mercaptopurine has been described, and may explain the results. Low TPMT activity in adult patients with inflammatory bowel disease correlated to an increased incidence of adverse drug reactions. However, there was no correlation between TPMT activity and the red blood cell concentrations of methylthioinosine monophosphate or thioguanine nucleotides, or between the concentrations of these metabolites and the occurrence of adverse effects. The results show that the role of thiopurine metabolism for drug effects is complex.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021625     DOI: 10.1097/00007691-200206000-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

Review 1.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 2.  Role of genetics in pediatric inflammatory bowel disease.

Authors:  David T Okou; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2014-10       Impact factor: 5.325

Review 3.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

4.  Correlation of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in Han Chinese patients treated with azathioprine 25 to 100 mg: A 1-year, single-center, prospective study.

Authors:  Bo Zhang; Xiao-Wei Xu; Xue-Jun Zeng; Da-Kui Li
Journal:  Curr Ther Res Clin Exp       Date:  2006-07

5.  Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Authors:  C Liu; W Yang; D Pei; C Cheng; C Smith; W Landier; L Hageman; Y Chen; J J Yang; K R Crews; N Kornegay; S E Karol; F L Wong; S Jeha; J T Sandlund; R C Ribeiro; J E Rubnitz; M L Metzger; C-H Pui; W E Evans; S Bhatia; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2016-11-18       Impact factor: 6.875

6.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

7.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

8.  Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression.

Authors:  Malin Lindqvist; Sven Almer; Curt Peterson; Peter Söderkvist
Journal:  Eur J Clin Pharmacol       Date:  2003-06-19       Impact factor: 2.953

9.  Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.

Authors:  Patricia Wennerstrand; Lars-Göran Mårtensson; Stefan Söderhäll; Anna Zimdahl; Malin Lindqvist Appell
Journal:  Eur J Clin Pharmacol       Date:  2013-05-10       Impact factor: 2.953

10.  Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age.

Authors:  Catherine Ganiere-Monteil; Yves Medard; Corinne Lejus; Béatrice Bruneau; Alain Pineau; Odile Fenneteau; Michel Bourin; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.